The Cancer Omics Atlas: an integrative resource for cancer omics annotations

BackgroundThe Cancer Genome Atlas (TCGA) is an important data resource for cancer biologists and oncologists. However, a lack of bioinformatics expertise often hinders experimental cancer biologists and oncologists from exploring the TCGA resource. Although a number of tools have been developed for facilitating cancer researchers to utilize the TCGA data, these existing tools cannot fully satisfy the large community of experimental cancer biologists and oncologists without bioinformatics expertise.MethodsWe developed a new web-based tool The Cancer Omics Atlas (TCOA, http://tcoa.cpu.edu.cn) for fast and straightforward querying of TCGA “omics” data.ResultsTCOA provides the querying of gene expression, somatic mutations, microRNA (miRNA) expression, protein expression data based on a single molecule or cancer type. TCOA also provides the querying of expression correlation between gene pairs, miRNA pairs, gene and miRNA, and gene and protein. Moreover, TCOA provides the querying of the associations between gene, miRNA, or protein expression and survival prognosis in cancers. In addition, TCOA displays transcriptional profiles across various human cancer types based on the pan-cancer analysis. Finally, TCOA provides the querying of molecular profiles for 2877 immune-related genes in human cancers. These immune-related genes include those that are established or promising targets for cancer immunotherapy such as CTLA4, PD1, PD-L1, PD-L2, IDO1, LAG3, and TIGIT.ConclusionsTCOA is a useful tool that supplies a number of unique and new functions complementary to the existing tools to facilitate exploration of the TCGA resource.

[1]  Jamie R. Kutasovic,et al.  Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer , 2013, Virchows Archiv.

[2]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[3]  M. Todaro,et al.  By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy , 2014, Oncotarget.

[4]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[5]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[6]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[7]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[8]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[9]  Akira Nakagawara,et al.  Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation* , 2004, Journal of Biological Chemistry.

[10]  Xiaoli Liu,et al.  Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in lung cancer and significant correlations with brain metastasis and natural killer cells , 2015, Molecular and Cellular Biochemistry.

[11]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[12]  Karin Breuer,et al.  InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation , 2012, Nucleic Acids Res..

[13]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[14]  Richard Simon,et al.  Identification of potential synthetic lethal genes to p53 using a computational biology approach , 2013, BMC Medical Genomics.

[15]  J. Chen,et al.  Multiple Roles of MicroRNA-100 in Human Cancer and its Therapeutic Potential , 2015, Cellular Physiology and Biochemistry.

[16]  Xiaosheng Wang,et al.  Transcriptional landscape of human cancers , 2017, Oncotarget.

[17]  Hejun Zhang,et al.  Associations of THBS2 and THBS4 polymorphisms to gastric cancer in a Southeast Chinese population. , 2016, Cancer genetics.

[18]  F. Fuller-Pace,et al.  p53-dependent repression of polo-like kinase-1 (PLK1) , 2010, Cell cycle.

[19]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[20]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[22]  Xiaosheng Wang,et al.  PLK1, A Potential Target for Cancer Therapy , 2016, Translational oncology.

[23]  A. Xia,et al.  High frequency of the IVS2-2A>G DNA sequence variation in SLC26A5, encoding the cochlear motor protein prestin, precludes its involvement in hereditary hearing loss , 2005, BMC Medical Genetics.

[24]  Jun Li,et al.  TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.

[25]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[26]  X. Qiu,et al.  Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma , 2016, Journal of experimental & clinical cancer research : CR.

[27]  Jana Jeschke,et al.  MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.